Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment.
Neurobiol Aging. 2010.
PMID: 20541287
Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2019 | 1 |
| 2024 | 0 |
Search Results
4 results
Results by year
Citations
1
article
found by citation matching
Search results
Filters applied: . Clear all
Page 1
Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment.
Lorenzi M, Donohue M, Paternicò D, Scarpazza C, Ostrowitzki S, Blin O, Irving E, Frisoni GB; Alzheimer's Disease Neuroimaging Initiative.
Lorenzi M, et al.
Neurobiol Aging. 2010 Aug;31(8):1443-51, 1451.e1. doi: 10.1016/j.neurobiolaging.2010.04.036. Epub 2010 Jun 11.
Neurobiol Aging. 2010.
PMID: 20541287
Clinical trials of disease modifying drugs for Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) might benefit from enrichment with true AD cases. Four hundred five MCI …
Clinical trials of disease modifying drugs for Alzheimer's disease (AD) in patients …
Item in Clipboard
Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers.
Marizzoni M, Ferrari C, Jovicich J, Albani D, Babiloni C, Cavaliere L, Didic M, Forloni G, Galluzzi S, Hoffmann KT, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Ribaldi F, Rossini PM, Schönknecht P, Salvatore M, Soricelli A, Hensch T, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB; PharmaCog Consortium.
Marizzoni M, et al.
J Alzheimers Dis. 2019;69(1):3-14. doi: 10.3233/JAD-180152.
J Alzheimers Dis. 2019.
PMID: 29914031
BACKGROUND: Early Alzheimer's disease (AD) detection using cerebrospinal fluid (CSF) biomarkers has been recommended as enrichment strategy for trials involving mild cognitive impairment (MCI) patients. ...CONCLUSION: …
BACKGROUND: Early Alzheimer's disease (AD) detection using cerebrospinal fluid (CSF) biomarkers has been recomme …
Item in Clipboard
Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease.
Kennedy RE, Cutter GR, Schneider LS.
Kennedy RE, et al.
Alzheimers Dement. 2014 May;10(3):349-59. doi: 10.1016/j.jalz.2013.03.003. Epub 2013 May 25.
Alzheimers Dement. 2014.
PMID: 23712001
Free PMC article.
BACKGROUND: The apolipoprotein E (APOE) epsilon4 genotype has been recommended as a potential inclusion or exclusion criterion in targeted clinical trials for Alzheimer's disease (AD) and mild cognitive impairment (MCI) resu …
BACKGROUND: The apolipoprotein E (APOE) epsilon4 genotype has been recommended as a potential inclusion or exclusion criterion in targeted …
Item in Clipboard
Amyloid and Tau Biomarkers in CSF.
Blennow K, Zetterberg H.
Blennow K, et al.
J Prev Alzheimers Dis. 2015;2(1):46-50. doi: 10.14283/jpad.2015.41.
J Prev Alzheimers Dis. 2015.
PMID: 29234775
The number of failed Alzheimer's disease (AD) clinical trials on Abeta-targeting drugs is increasing. ...The focus of this review is on the possible role of cerebrospinal fluid (CSF) biomarkers in AD clinical trials f …
The number of failed Alzheimer's disease (AD) clinical trials on Abeta-targeting drugs is increasi …
Item in Clipboard
Cite
Cite